Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hadasit Bio HoldingsHSITF 14 3-Year EBITDA Growth Rate is 62.10% as of Dec. 2025, which is 97% above its 10-year median of 31.50. GuruFocus rates HSITF with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Hadasit Bio Holdings ranks better than 90.63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 62.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hadasit Bio Holdings was 80.60% per year. The lowest was -238.50% per year. And the median was 31.50% per year.
Hadasit Bio Holdings (OTCPK:HSITF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hadasit Bio Holdings 3-Year EBITDA Growth Rate Related Terms
HSITF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Hadasit Bio Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hadasit Bio Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hadasit Bio Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hadasit Bio Holdings's 3-Year EBITDA Growth Rate falls into.
Hadasit Bio Holdings 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 62.10% mean?
Hadasit Bio Holdings (HSITF) has a 3-Year EBITDA Growth Rate of 62.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hadasit Bio Holdings and its competitors. This is 97% above median its historical median of 31.50. According to the industry distribution chart, Hadasit Bio Holdings ranks #106 out of 1131 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Hadasit Bio Holdings' 3-Year EBITDA Growth Rate too high?
Hadasit Bio Holdings' current 3-Year EBITDA Growth Rate of 62.10% is 97% above median its 10-year median of 31.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Hadasit Bio Holdings' value of 62.10% is 316.8% above this industry median. Based on the distribution chart, Hadasit Bio Holdings ranks #106 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hadasit Bio Holdings has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Hadasit Bio Holdings' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hadasit Bio Holdings ranks #106 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Hadasit Bio Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Hadasit Bio Holdings' value of 62.10% is 316.8% above this benchmark. While the company's 10-year median is 31.50 vs. the industry median of 14.90, Hadasit Bio Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hadasit Bio Holdings's current 3-Year EBITDA Growth Rate of 62.10% is 316.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hadasit Bio Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hadasit Bio Holdings's current 3-Year EBITDA Growth Rate is 62.10%, which is 97% above median its own 10-year median of 31.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hadasit Bio Holdings stock overvalued right now?
Hadasit Bio Holdings (HSITF) has a current 3-Year EBITDA Growth Rate of 62.10%. The current 3-Year EBITDA Growth Rate is 62.10%, which is 97% above median its 10-year median of 31.50 and 316.8% above the Biotechnology industry median of 14.90. Hadasit Bio Holdings' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hadasit Bio Holdings (HSITF), the current 3-Year EBITDA Growth Rate is 62.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hadasit Bio Holdings Ltd serves as a precedent in the field of biotech financing. It is engaged in the advancement and enhancement of its portfolio companies. Its portfolio companies are involved in the field of medical and biotechnological research and production and distribution of the results of the research and development done in these areas.
14GF Score
Get the complete analysis for HSITF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSITF has been successfully added to your 
